Navigation Links
NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones

ANN ARBOR, Mich., March 6 /PRNewswire/ -- NanoBio(R) Corporation has received its third $10 million tranche of equity funding from Perseus LLC, after having successfully met three critical development milestones: validating the efficacy and safety of its two topical treatments for skin infections and demonstrating the strength of its influenza vaccine in ferret studies.

The company, a spin-off from the University of Michigan, has received a total of $30 million over the past 18 months from Perseus LLC, a leading private equity management firm. The funding has enabled NanoBio to conduct phase 2 clinical trials on its two lead products, topical lotions NB-001 for herpes labialis (cold sores) and NB-002 for onychomycosis (nail fungus). Additionally, the funding has supported extensive animal studies supporting the company's nasal vaccines against influenza, hepatitis B and several additional pathogens.

Preliminary analyses of the data demonstrate the lotions have potent antiviral and antifungal effects without safety concerns or systemic absorption, according to NanoBio scientists.

Phase 2a and Phase 2b clinical trials on NB-001 are complete, while phase 2 clinical trials on NB-002 are in progress and will be completed by the first quarter of 2009. Final data will be presented after the data have undergone peer review processes.

"We're delighted by the considerable progress NanoBio has achieved in all dimensions, most notably its efficacy and safety data in the clinical realm," said Norman C. Selby, senior managing director at Perseus. "We are also pleased that the company has built a sound business infrastructure and a robust research program in the vaccine arena.

"The company's platform technology is proving to be highly effective in combating a broad range of viruses, bacteria and fungi, and we're eagerly anticipating the next round of data on its vaccine studies," he added.

Based on the positive data, NanoBio will move immediately to plan phase 3 testing of NB-001, said James R. Baker Jr., M.D., founder and chairman of NanoBio Corporation.

About NanoBio

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
2. CEL-SCI Corporation Reports First Quarter Financial Results
3. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
8. CEL-SCI Corporation Announces 2007 Financial Results
9. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology:
(Date:10/13/2015)... Alexandria, Va. — , ... ... Military Officers Association of America (MOAA) will hold its 2015 ... Highlights include a free military career fair; informational seminars; a ... chairman of the Joint Chiefs of Staff; and the Community ...
(Date:10/13/2015)... ... October 13, 2015 , ... Vision Group Holdings, the ... San Diego, California. With brands including The LASIK Vision Institute and TLC Laser Eye ... the nationwide leader in laser vision correction. , Global Laser Vision will continue to ...
(Date:10/13/2015)... Nashville, Tennessee (PRWEB) , ... October 13, 2015 ... ... owned leader of anesthesia and pain management services, today announced its partnership with ... the partnership integrates data from disparate systems and organizes the data into an ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded design services ... the industry’s first RGB-IR pixel format camera with a USB 3.0 interface and ... family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a ...
Breaking Medicine News(10 mins):